Anixa Biosciences Inc financial data

Symbol
ANIX on Nasdaq
Industry
Pharmaceutical Preparations
Location
3150 Almaden Expressway, Suite 250, San Jose, CA
State of incorporation
DE
Fiscal year end
October 31
Former names
ITUS Corp (to 9/27/2018), COPYTELE INC (to 8/27/2014)
Latest financial report
10-Q - Q4 2024 - Mar 11, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.06K % -27.9%
Debt-to-equity 10.7 % +42.3%
Return On Equity -63.3 % -43.6%
Return On Assets -56.9 % -39.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 32.2M shares +0.93%
Common Stock, Shares, Outstanding 32.2M shares +1.39%
Entity Public Float 90.6M USD -24.9%
Common Stock, Value, Issued 322K USD +1.26%
Weighted Average Number of Shares Outstanding, Basic 32.2M shares +2.39%
Weighted Average Number of Shares Outstanding, Diluted 32.2M shares +2.39%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 210K USD
Revenue from Contract with Customer, Excluding Assessed Tax 210K USD
Research and Development Expense 6.6M USD +30.7%
General and Administrative Expense 7.01M USD -0.77%
Costs and Expenses 13.6M USD +10.9%
Operating Income (Loss) -13.6M USD -12.8%
Net Income (Loss) Attributable to Parent -12.5M USD -16.2%
Earnings Per Share, Basic -0.39 USD/shares +22%
Earnings Per Share, Diluted -0.39 USD/shares +22%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.05M USD +5.51%
Cash, Cash Equivalents, and Short-term Investments 20.7M USD
Assets, Current 18.7M USD -25.9%
Operating Lease, Right-of-Use Asset 220K USD +43.8%
Assets 18.9M USD -25.5%
Accounts Payable, Current 600K USD +64.8%
Accrued Liabilities, Current 1.36M USD +9.74%
Liabilities, Current 2M USD +20.4%
Operating Lease, Liability, Noncurrent 194K USD +79.6%
Liabilities 2.19M USD +24%
Retained Earnings (Accumulated Deficit) -244M USD -5.39%
Stockholders' Equity Attributable to Parent 17.9M USD -27.4%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 16.7M USD -29.2%
Liabilities and Equity 18.9M USD -25.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.9M USD -25.8%
Net Cash Provided by (Used in) Financing Activities -17K USD -101%
Net Cash Provided by (Used in) Investing Activities 2.7M USD +1995%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 32.2M shares +1.39%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -218K USD -363%
Deferred Tax Assets, Valuation Allowance 34.5M USD +16.6%
Deferred Tax Assets, Gross 34.5M USD +16.6%
Operating Lease, Liability 230K USD +42%
Lessee, Operating Lease, Liability, to be Paid 303K USD +62.9%
Operating Lease, Liability, Current 36K USD -33.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 64K USD -1.54%
Lessee, Operating Lease, Liability, to be Paid, Year One 63K USD -10%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 73K USD +204%
Lessee, Operating Lease, Liability, to be Paid, Year Three 66K USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 19.9K shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 63K USD
Additional Paid in Capital 261M USD +2.24%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 100 USD/shares 0%